Cagent Vascular: Cagent Vascular Announces Launch of New Product Serranator SL-PRO for CLTI and Pedal Disease

WAYNE, Penn., February 03, 2025 --( BUSINESS WIRE )--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the launch of its newest product, Serranator SL-PRO PTA Serration Balloon Catheter. Serranator SL-PRO is purpose-built for pedal intervention as well as challenging-to-cross tibial disease. Serranator SL-PRO utilizes Cagent's proven Serration Technology on a redesigned platform offering improved deliverability and trackability 1 , while offering Serranator's proven 1,000 times increase in point force versus plain balloon. Its innovative mechanism of action allows for predictable and controlled lumen gain with minimal dissection. Dr. Michael Lichtenberg (Chief Medical Officer and Director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany) said, "As an experienced Serranator operator, my team has grown accustomed to the benefits of Serration including great lumen gain, low complication rate, and low 6% BTK vessel recoil vs. 55% measured recoil with Plain Balloon 2 ." Dr. Lichtenberg continued, "We also appreciate Serranator's ability to safely and effectively treat complex disease, even down into the pedal arteries. With SL-PRO, we're eager to experience the advantages of Serranation in this new, more deliverable platform." Cagent Vascular Chairman and CEO Brian Walsh added, "We are committed to consistently developing and advancing solutions for physicians treating PAD patients, and winning the fight against this debilitating disease. With over 20,000 Serranation procedures now completed and a growing library of clinical data, Serranator has proven itself to be a valuable tool in this fight. The Serranator SL-PRO is a purpose-built tool for pedal intervention, and with it, the Serranator product family can now treat from hip to toe." The Serranator ® and Serranator SL-PRO PTA Serration Balloon Catheters are FDA-cleared, novel balloons using proprietary stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies. For ordering information, please visit https://cagentvascular.com/ or contact info@cagentvascular.com 1 TD-0761 Serranator SL-PRO Independent Product Performance Report. 2 Fereydooni A, Chandra V, Schneider PA, Giasolli R, Lichtenberg M, Stahlhoff S. Serration Angioplasty Is Associated With Less Recoil in Infrapopliteal Arteries Compared With Plain Balloon Angioplasty. J Endovasc Ther. 2023 Dec 7:15266028231215284. View source version on businesswire.com: https://www.businesswire.com/news/home/20250203233782/en/ Contacts Cagent Communications and Media Contact: Lauren Pfeiffer +1 610-688-2006 LPfeiffer@cagentvascular.com